Status: Recruiting
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.
Participants needed: 30
Trial details
Phase: Phase 1Biological sex: MaleType: InterventionalSponsor: Jonsson Comprehensive Cancer CenterUpdated: Jun 15, 2026Locations: 1
Eligibility criteria
Volunteer patient [+6]
Patients with significant congenital or acquired bleeding disorders (e.g. von Wi...